These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2164251)

  • 1. [Simple coagulation prophylaxis using low-molecular heparin enoxaparin in pediatric hemodialysis].
    Bianchetti MG; Speck S; Müller R; Oetliker OH
    Schweiz Rundsch Med Prax; 1990 Jun; 79(23):730-1. PubMed ID: 2164251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anticoagulation of the extracorporeal circuit in chronic hemodialysis].
    Ryckelynck JP; Chouraqui D; Lobbedez T
    Nephrologie; 1998; 19(4):223-5. PubMed ID: 9675763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Enoxaparin in the prevention of thrombosis of extracorporeal circulation during dialysis of patients with chronic renal failure].
    Pouzol P; Dechelette E; Jurkovitz C; Kuentz F; Polack B
    Rev Med Interne; 1988; 9(3):321-6. PubMed ID: 2841741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
    Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
    Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis.
    Klejna K; Naumnik B; Koc-Żórawska E; Myśliwiec M
    Clin Appl Thromb Hemost; 2014 May; 20(4):433-41. PubMed ID: 23104956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of heparins in end-stage renal disease.
    Sonawane S; Kasbekar N; Berns JS
    Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of low-dose low molecular weight heparin in hemodialysis.
    Lai KN; Wang AY; Ho K; Szeto CC; Li M; Wong LK; Yu AW
    Am J Kidney Dis; 1996 Nov; 28(5):721-6. PubMed ID: 9158210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis.
    Lazrak HH; René É; Elftouh N; Leblanc M; Lafrance JP
    BMC Nephrol; 2017 Jun; 18(1):187. PubMed ID: 28592259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center.
    Lord H; Jean N; Dumont M; Kassis J; Leblanc M
    Am J Nephrol; 2002; 22(1):58-66. PubMed ID: 11919404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative study of low molecular weight heparin and unfractionated heparin in patients on maintenance hemodialysis].
    Noguchi M; Izumi K; Deguchi K; Endoh T; Tsuda M; Shirakawa S
    Rinsho Byori; 1990 Jul; Suppl 86():177-83. PubMed ID: 2172594
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
    Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
    Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular-weight heparin for routine hemodialysis.
    Davenport A
    Hemodial Int; 2008 Oct; 12 Suppl 2():S34-7. PubMed ID: 18837768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use in hemodialysis and hemofiltration of CY 216 (Fraxiparine) administered via intravenous bolus in patients with acute and chronic renal insufficiency with and without hemorrhagic risk].
    Steinbach G; Bosc C; Caraman PL; Azoulay E; Olry L; D'Azemar P; Chopin J
    Nephrologie; 1990; 11(1):17-21. PubMed ID: 2165223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antithrombotic activity of low molecular weight heparin (enoxaparin) during hemodialysis in patients with terminal kidney failure].
    Przedlacki J; Bogdańska-Straszyńska B; Sawicka B; Włodarczyk D; Sladowska B; Ajewski M; Wasiak K; Gellert R
    Pol Arch Med Wewn; 1994 Jun; 91(6):438-45. PubMed ID: 7971464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of single dose low-molecular-weight heparin in long hemodialysis.
    Lai KN; Ho K; Li M; Szeto CC
    Int J Artif Organs; 1998 Apr; 21(4):196-200. PubMed ID: 9649059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of anticoagulation on blood membrane interactions during hemodialysis.
    Hofbauer R; Moser D; Frass M; Oberbauer R; Kaye AD; Wagner O; Kapiotis S; Druml W
    Kidney Int; 1999 Oct; 56(4):1578-83. PubMed ID: 10504511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis.
    Liu ZQ; Wang L
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct; 22(10):942-3. PubMed ID: 12377628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Present opinions concerning the administration of low molecular weight heparins in hemodialysis patients].
    Drozdz M; Kowalczyk-Michałek M; Kraśniak A; Sułowicz W
    Przegl Lek; 2005; 62(4):257-9. PubMed ID: 16229247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A low molecular weight heparin in hemodialysis.
    Maurin N; Kierdorf H
    Klin Wochenschr; 1988 Mar; 66(6):246-9. PubMed ID: 2835544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.